Although the traditional nearly decade-long clinical trial timelines completely collapsed during COVID, this truncating was not necessarily novel. Precedent exists for accelerating approval timelines during health emergencies such as the AIDs/HIV epidemic, where Compound S, a re-make of AZT, or azidothymidine, originally developed to fight cancer, became controversially fast-tracked after the discovery that it could block HIV activity. Likewise, when potentially lifesaving drugs are
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Unlearn Raises $50M to Accelerate AI-Powered Clinical Trials with Digital Twins
What You Should Know:
- Unlearn®, a leading AI company using digital twins to revolutionize clinical trials, announced today a $50M Series C funding round led by Altimeter Capital. This investment, bringing Unlearn's total funding to over $130M, will fuel its mission to eliminate trial and error in medicine through faster, smaller, and more ethical clinical trials.
- Unlearn collaborates with pharmaceutical companies, biotechs, and academic institutions to optimize and streamline clinical
Read More
Verily Appoints Myoung Cha as Chief Product Officer
What You Should Know:
- Verily, an Alphabet precision health technology company appoints Myoung Cha as Chief Product Officer.
- As Chief Product Officer at Verily, Cha will lead strategy and development across the company’s care (Verily Onduo), research (Verily Viewpoint), and products (Verily Numetric) portfolio.
Cha Bio/Background
Cha has more than twenty years of experience building and implementing innovative technology solutions to advance clinical research, transform patient
Read More
H1 Unveils GenosAI Pro: Supercharging Clinical Trials with Conversational AI
What You Should Know:
- H1, the go-to resource for healthcare professionals, clinical trial information, and life sciences research, announced the launch of its conversational AI tool GenosAI Pro.
- The conversational AI tool empowers pharmaceutical companies to streamline workflows, enhance data-driven decision-making, and optimize clinical trial processes within the Trial Landscape platform.
Transforming Clinical Trial Design
Building upon the success of GenosAI Lite, GenosAI Pro
Read More
Helio Genomics Appoints Gary Frazier as Chief Growth Officer
What You Should Know:
- Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology for cancer detection, has appointed Gary Frazier as its Chief Growth Officer.
- Frazier's appointment at Helio Genomics underscores the company's commitment to strategic growth and innovation. His leadership will be instrumental in shaping the firm's trajectory, including strategic business planning, growth strategies, integrated delivery systems, and more.
Gary Frazier
Read More
Inovalon Acquires VigiLanz, Expanding Reach in Clinical Surveillance and Patient Safety
What You Should Know:
- Inovalon, a provider of cloud-based healthcare data analytics solutions, announced today the acquisition of VigiLanz, a prominent provider of SaaS-based clinical surveillance and patient safety software.
- This acquisition signifies Inovalon's commitment to driving innovation and empowering healthcare stakeholders with data-driven solutions. By integrating VigiLanz's expertise, Inovalon aims to enhance patient safety, optimize healthcare costs, and ultimately
Read More
Pharma & Influencer Marketing: Can They Coexist Ethically?
Influencer marketing in the pharmaceutical industry is a complex issue with reasonable arguments on multiple sides. On the one hand, leveraging individual patients' personal experiences and narratives may help bring an authentic voice to product messaging. This could increase trust and resonance for some audiences skeptical of more traditional promotional content. However, legitimate concerns about transparency and potential conflicts of interest exist if affiliate relationships or sponsored
Read More
23andMe Scores FDA Clearance for Novel Cancer Immunotherapy Targeting NK Cells
What You Should Know:
- 23andMe Holding Co. (Nasdaq: ME), a genetics and biopharmaceutical company, announced The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for 23ME-01473 (referred to as '1473), paving the way for the first human clinical trial of this promising new therapy.
- With FDA clearance secured, 23andMe plans to initiate a Phase 1 clinical trial in the first half of 2024. This initial study will evaluate the safety and
Read More
PathAI Expands PathExplore Reach to 14 Cancer Types, Fueling Precision Oncology
What You Should Know:
- PathAI, a pioneer in AI-powered pathology, announced a significant expansion of its PathExplore platform, adding six new oncology indications to its arsenal.
- The expansion doubles the platform's reach, now covering 14 different cancer types, and further solidifies PathExplore as the leading tool for characterizing the tumor microenvironment (TME) from H&E-stained whole-slide images (WSIs).
Bridging the Gap in Cancer Research
Despite advances in cancer
Read More
Personalis and ClearNote Join Forces for Early Cancer Detection
What You Should Know:
Personalis, Inc., a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform.
Revolutionizing Cancer Detection and Treatment: ClearNote Health's Epigenomics Platform
ClearNote Health's Epigenomics Platform is a
Read More
